Oct. 17 at 2:20 AM
$AFMD per Gilde
- Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing the company with one of the most mature pipelines in the innate immune oncology field. The company’s lead product candidate has demonstrated transformational data in patients suffering from end-stage Hodgkin’s lymphoma. If these results can be replicated, Affimed has the potential to lead a paradigm shift in oncology by offering a life-changing new treatment option for thousands of patients.
In addition,
- Affimed’s second product candidate has shown very promising data in end-stage lung cancer patients, a group that is rapidly growing and for which treatment options are virtually non-existent. Affimed’s pipeline is based on its proprietary ROCK® platform, which enables the destruction of tumors in a targeted manner.
- Affimed’s 3rd product, innate cell engager AFM28, eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. Nothing else close.